Rahim-Mahdy Haleema, Seifert Roland
Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625, Hannover, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 7. doi: 10.1007/s00210-025-04392-5.
Historically prominent in Ayurvedic cultures, turmeric (Curcuma longa), or "Haldi," is renowned for its anti-inflammatory and antioxidant effects, mainly due to its active compounds, curcuminoids. Due to the increasing use of turmeric supplements, this study critically examined 125 preparations across the UK, USA, India, Australia, and Germany and evaluated their compliance with evidence-based recommendations. Results reveal significant regulatory and labeling inconsistencies across countries, with 34% of preparations failing to disclose the active curcuminoid content. This lack of dosage regulation is especially concerning when considering the ongoing research into advanced delivery systems-such as nanoparticles, liposomes, micelles, and phospholipid complexes-which significantly enhance curcumin's absorption. Curcumin, a hydrophobic compound, undergoes rapid metabolism in the liver through Phase I and II detoxification pathways, particularly via cytochrome P450 enzymes and UDP-glucuronosyltransferase enzymes. This results in limited bioavailability, as curcumin is rapidly converted to water-soluble metabolites and excreted, reducing its effectiveness at therapeutic doses. However, through modern formulation technologies, curcumin can potentially not only alter drug metabolism, but its antioxidant action via Nrf2 activation can shift to pro-oxidant effects at high doses, causing oxidative stress and the accumulation of reactive metabolites. Emerging evidence suggests chronic low-dose use may lead to gastrointestinal, hepatic, or renal toxicity, yet turmeric preparations, falling within the scope of food law, lack the stringent controls applied to pharmaceuticals and are generally assumed safe. This study highlights the need for transparent labeling, clear dosage guidelines, and an understanding of curcumin's metabolic profile to guide consumers in maximizing benefits while mitigating risks. Furthermore, it aims to assist healthcare professionals in making informed recommendations regarding curcumin supplementation. Further research must include long-term clinical trials and potential standardization of curcumin supplement formulations.
姜黄(Curcuma longa),即“哈尔迪”,在阿育吠陀文化中历史悠久,因其抗炎和抗氧化作用而闻名,这主要归功于其活性成分姜黄素类化合物。由于姜黄补充剂的使用日益增加,本研究严格检查了英国、美国、印度、澳大利亚和德国的125种制剂,并评估了它们是否符合循证建议。结果显示,各国在监管和标签方面存在显著不一致,34%的制剂未披露活性姜黄素类化合物的含量。考虑到正在对纳米颗粒、脂质体、胶束和磷脂复合物等先进给药系统进行研究,而这些系统能显著提高姜黄素的吸收,这种缺乏剂量监管的情况尤其令人担忧。姜黄素是一种疏水化合物,在肝脏中通过I相和II相解毒途径进行快速代谢,特别是通过细胞色素P450酶和尿苷二磷酸葡萄糖醛酸基转移酶。这导致生物利用度有限,因为姜黄素会迅速转化为水溶性代谢物并排出体外,从而降低其在治疗剂量下的有效性。然而,通过现代制剂技术,姜黄素不仅有可能改变药物代谢,而且其通过激活Nrf2产生的抗氧化作用在高剂量时可能会转变为促氧化作用,导致氧化应激和活性代谢物的积累。新出现的证据表明,长期低剂量使用可能会导致胃肠道、肝脏或肾脏毒性,然而,属于食品法范畴的姜黄制剂缺乏适用于药品的严格管制,并且通常被认为是安全的。本研究强调需要透明的标签、明确的剂量指南,以及对姜黄素代谢概况的了解,以指导消费者在将益处最大化的同时降低风险。此外,它旨在帮助医疗保健专业人员就姜黄素补充剂提出明智的建议。进一步的研究必须包括长期临床试验以及姜黄素补充剂制剂的潜在标准化。